Top 4 Challenges for Vaccine Manufacturers

Recently we undertook the research for the 15th annual World Vaccine Congress, and so asked what the biggest challenges are for each segment of the market. When we spoke to vaccine manufacturers, these came up as the 4 biggest issues:   1)      Adjuvants Adjuvants are often lauded as the way forward to make vaccines more effective, but given how new …

Braasch Biotech Continues to Build Patent Portfolio With Acceptances in the European Union, Russia and Israel

April 28, 2014 Braasch Biotech LLC, a biopharmaceutical company developing and commercializing anti-somatostatin vaccines, today announced that it has received Notices of Acceptance from the European, Russian and Israeli Patent Offices for a patent covering the use of Braasch’s product candidate, JH14-Somatovac®. The vaccine is indicated for use in farmed animals and safely enhances the target animal’s own ability to produce …

Dendreon Plans to Make PROVENGE Available in Europe

March 3, 2014 Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom. Dendreon will make PROVENGE commercially available to patients within the approved label through Centers of Excellence using its Contract Manufacturing Organization, PharmaCell. Centers of Excellence are institutions where a high volume of prostate cancer …